SCHEMBL21095694

SCHEMBL21095694

O=C(C[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 10/20 1.00
KCNH2 Q12809 4/20 0.66
CHRM2 P08172 2/20 0.54
CHRM1 P11229 2/20 0.54
CACNA1F O60840 1/20 0.54
CHRM4 P08173 1/20 0.54
CHRM5 P08912 1/20 0.54
KCNE1 P15382 1/20 0.54
KCNQ1 P51787 1/20 0.54
CACNA1D Q01668 1/20 0.54
CACNA1S Q13698 1/20 0.54
CACNA1C Q13936 1/20 0.54
SCN5A Q14524 1/20 0.54
KCND3 Q9UK17 1/20 0.54
TRPM8 Q7Z2W7 1/20 0.52
HHAT Q5VTY9 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21095692 1.00 CHRM3 (1.00) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL23436379 1.00 CHRM3 (1.00) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL10050700 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL23436347 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL23436034 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL13960533 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL21095728 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL25607842 0.92 CHRM3 (0.84) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL23435978 0.90 CHRM3 (0.82) CHRM3KCNH2CHRM2CHRM1CACNA1F
SCHEMBL23436042 0.90 CHRM3 (0.82) CHRM3KCNH2CHRM2CHRM1CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239892-A1 COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF ARKUDA THERAPEUTICS (US) 2023-12-14 WO disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 EP disclosed
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2021-06-03 US disclosed
WO-2019118528-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN1 CHRM3 4330/4885KCNH2 4879/4885CHRM2 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.